Reported about 1 year ago
In a recent interview, 70-year-old founder of Ruichi Biotech Group, He Chongren, talked about developing a Digital Bio Barcode (BMB) and obtaining FDA approval in the U.S. for multiple diagnostic reagents. The company aims to go beyond the current list of diseases detectable and focus on using just a drop of blood to predict cancer relapse. The innovative technology allows for efficient and cost-effective testing, with one sample revealing a range of viruses within a short timeframe. Ruichi's cutting-edge approach has the potential to revolutionize medical diagnostics and treatment.
Source: YAHOO